
A new FDA-approved device could change how Americans lose weight
Once the sole domain of people with diabetes, glucose monitors are gaining popularity as a health tracking accessory not that different from an Apple Watch or an Oura Ring. On Wednesday, the FDA approved a glucose monitoring system from the startup Signos for weight management – a first for the tech, which represents a growing corner of the digital wellness space.
'Everyone deserves access to insights that help them live healthier, longer, more vibrant lives,' Signos CEO Sharam Fouladgar-Mercer said in a press release. 'Signos isn't just about data; it's about giving people ownership over their health and weight journeys in a way never before seen.'
Signos designed an app that sets glucose range goals based on individual needs and tailors them over time, encouraging its users to make healthy lifestyle choices to meet them. The app pairs with the Stelo continuous glucose monitor (CGM) sensor patch made by Dexcom, which already sells its devices over the counter for around $100 a month.
'This is the first-ever FDA clearance for a system for weight that isn't a pharmacological intervention, isn't a surgical intervention,' Fouladgar-Mercer told STAT.
FDA approval is an expensive, time-intensive process, but obtaining the clearance means a Signos subscription could be covered by HSA and FSA plans and potentially be reimbursed by insurance in the future. Signos sells its plans for $129 for six months, which includes glucose sensors and access to its app, which converts real-time blood sugar data into health insights and tips.
The company can also now boast about being the 'world's first and only FDA-cleared app and CGM for weight management and wellness,' which might take it pretty far in a soon-to-be crowded market. As is the case with all technology these days, Signos uses AI to offer personalized recommendations based on the data it logs. Users can also track their food and exercise within the company's app, blending that data with glucose monitoring to make changes to their behavior and diet.
Fouladgar-Mercer believes that bariatric surgery patients and some people using GLP-1s for weight loss will want the additional insights possible with the Signos app. The app also offers an alternative non-pharmaceutical path for people looking for new ways to succeed in their weight management goals, and could provide an off-ramp for former GLP-1 users looking to maintain their results with behavioral changes.
One piece of the MAHA movement
Obsessively quantifying the self right down to your blood sugar levels isn't everyone's cup of tea, but it is a major health goal for the Trump administration. Health and Human Services Secretary Robert F. Kennedy Jr. is championing health tracking devices as part of the Make America Healthy Again movement, which is pursuing disparate health goals from regulating ultra-processed foods to investigating well-studied vaccines, sowing doubt about life-saving shots in the process.
'It's a way… people can take control over their own health. They can take responsibility,' Kennedy said at a recent House Subcommittee on Health hearing. 'They can see, as you know, what food is doing to their glucose levels, their heart rates and a number of other metrics as they eat it, and they can begin to make good judgments about their diet, about their physical activity, about the way that they live their lives.'
Beyond RFK Jr., the U.S. government is poised to have a major glucose tracking booster in the administration. In June, Trump swapped his previous surgeon general nominee out in favor of Dr. Casey Means, a wellness industry figure who co-founded a blood glucose monitoring startup called Levels. Like Signos, that company sells subscription access to an app, pairing custom software with off-the-shelf glucose monitors made by Dexcom. Unlike Signos, Levels is not FDA approved for weight management and is marketed for general wellness.
Kennedy, a skeptic of weight loss drugs, has advocated for dietary and behavioral changes over GLP-1s to reverse the most worrying U.S. health trends. 'We think that wearables are a key to the MAHA agenda — Making America Healthy Again,'' Kennedy said. 'My vision is that every American is wearing a wearable within four years.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
2 minutes ago
- Medscape
Endometriosis Diagnosis Linked to Higher Self-Harm Risk
TOPLINE: Individuals diagnosed with endometriosis showed a 42% higher risk for self-harm, overdose, or suicide than matched control individuals, with risk particularly elevated among those with minimal prior psychiatric care. The study of 56,053 endometriosis patients and 112,106 controls revealed that those with no or minimal previous mental health services had nearly double the risk. METHODOLOGY: Researchers conducted a population-based, retrospective, matched cohort study using administrative health data from Ontario, Canada, spanning January 2010 to July 2022. Analysis included 56,053 women aged 18-50 years with first-time endometriosis diagnosis, matched 1:2 with 112,106 control individuals based on age, sex, census subdivision, psychiatric utilization gradient, and self-harm history. Primary outcome measures encompassed a composite of intentional self-harm, poisoning or overdose of accidental or unknown intent, and suicide, with data for suicide outcomes available until December 31, 2018. Psychiatric utilization in the 2 years before diagnosis was quantified using a gradient: no psychiatric utilization, outpatient care, emergency department visits, or hospital admission. TAKEAWAY: Endometriosis was associated with an increased risk for the composite outcome (adjusted hazard ratio [AHR], 1.42; 95% CI, 1.27-1.59), showing particularly strong association in individuals with no prior psychiatric care (AHR, 1.88; 95% CI, 1.54-2.30). Patients with endometriosis showed elevated risks for both intentional self-harm (AHR, 1.37; 95% CI, 1.22-1.54) and poisoning or overdose (AHR, 1.42; 95% CI, 1.29-1.56). The cumulative incidence of the primary composite outcome reached 2.5% in endometriosis patients compared with 1.8% in unexposed individuals. According to the researchers, no statistically significant elevation in risk was detected in individuals with higher baseline psychiatric utilization, though absolute incidence of all outcomes increased with the psychiatric utilization gradient. IN PRACTICE: 'These findings highlight the importance of considering mental health needs for patients newly diagnosed with endometriosis,' the authors of the study wrote. SOURCE: The study was led by Peter Thiel, MD, MPH, Department of Obstetrics and Gynecology, University of Saskatchewan in Saskatoon, Saskatchewan, Canada. It was published online in Obstetrics & Gynecology. LIMITATIONS: The administrative data used may be misclassified and lacks clinical information such as endometriosis severity, treatment responses, and lag between symptom onset and diagnosis. These gaps limit a more nuanced understanding of the relationship between endometriosis and self-harm outcomes. DISCLOSURES: The study was supported by ICES, which receives annual funding from the Ontario Ministry of Health and the Ministry of Long-Term Care. Ally Murji disclosed serving on the advisory board and speaker bureau for AbbVie, Bayer, and Pfizer. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
30 minutes ago
- Yahoo
OffSec and Deloitte Collaborate to Strengthen Asia's Cyber Defences Through Workforce Development
NEW YORK, Aug. 21, 2025 /PRNewswire/ -- OffSec Services Ltd ("OffSec"), a leading global provider of cybersecurity training and certifications, is pleased to announce a strategic collaboration with Deloitte. This partnership will deliver advanced, real-world cybersecurity training programs across Asia, directly addressing the rising cyber threats and the ongoing shortage of skilled cybersecurity professionals. The collaboration unites OffSec's reputation for developing cybersecurity professionals with a focus on technical skill and adversary mindset, with Deloitte's enterprise cybersecurity expertise and regional insights. Together, OffSec and Deloitte aim to provide a high-impact training experience that equips security practitioners, enterprise teams, and aspiring professionals with the offensive and defensive capabilities needed to tackle today's most urgent security challenges. "Cybersecurity today demands more than awareness and a modern tech stack — it requires hands-on capability, continuous upskilling, and readiness for real-world, real-time threats. Through this exciting strategic partnership, OffSec brings our industry-leading simulation and skills development, combined with Deloitte's deep client, industry, and regulatory insight. Together, we're enabling more effective large-scale cyber transformations by building resilient, enterprise-grade security teams prepared to meet the evolving threat landscape." said Matt Collins, VP of APAC, OffSec. The training programmes will cover a wide range of advanced topics, including penetration testing, ethical hacking, exploit development, application and infrastructure security, and incident response. Courses will be delivered by certified instructors and conducted through OffSec's proven hands-on lab environments, while also incorporating Deloitte's business-contextualised scenarios and case studies. This ensures that participants not only gain technical proficiency but are also able to apply that knowledge in real-world operational settings. For organisations facing growing regulatory scrutiny and increasingly sophisticated attacks, the collaboration offers a scalable solution to upskilling their cybersecurity teams with globally respected certifications and battle-tested techniques. The initial rollout will begin in Singapore, with future expansion planned across key Asia Pacific markets. "As the threat environment is becoming increasingly complex and the talent gap is growing wider, this collaboration with OffSec addresses both challenges by providing practical, career-relevant training that builds technical depth while helping organisations establish a culture of security that is grounded in operational capability," said Lim Kim Hwee, Executive Director, Deloitte Learning Solutions. OffSec and Deloitte's shared mission through this collaborative effort is to elevate the cybersecurity profession across the region by making expert-level training more accessible, relevant, and aligned with the evolving needs of enterprises and regulators. With this collaboration, the two organisations are setting a new standard for how cybersecurity talent development should be approached: technically rigorous, business-aware, and regionally informed. About OffSec Services LtdOffSec is the leading provider of continuous professional and workforce development, training, and education for cybersecurity practitioners. OffSec's distinct pedagogy and practical, hands-on learning help organizations fill the infosec talent gap by training their teams on today's most critical skills. With the OffSec Learning Library featuring 7,000 hours of content, including over 1,800 videos, and 4,200+ labs. OffSec demonstrates its commitment to empowering individuals and organizations to fight cyber threats with indispensable cybersecurity skills and resources. OffSec also funds and maintains Kali Linux, the leading operating system for penetration testing, ethical hacking, and network security assessments. For more information, visit and follow us on X and LinkedIn. For media inquiries, please contact:Contact Person: Damian GohEmail: | View original content: SOURCE OffSec Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
31 minutes ago
- Medscape
Aspirin Confers No Long-Term Heart Benefits in Older Adults
TOPLINE: Healthy older adults who received aspirin experienced no significant long-term benefits against major adverse cardiovascular events (MACE); the rates of major hemorrhage were higher among users of aspirin than among users of placebo. METHODOLOGY: Guidelines advise against routine initiation of aspirin for primary prevention of atherosclerotic cardiovascular disease events in older adults, yet many continue to use it. The long-term effects of using aspirin in this population remain uncertain. Researchers analyzed data from 15,668 older adults from Australia and the US who took part in the ASPREE trial (median age at the end of the trial, 79 years; 43.1% men) to assess the post-trial and long-term effects of aspirin on cardiovascular events. At enrollment, the participants had no history of cardiovascular events, dementia, or any physical disability that limited their independence. The participants were randomly assigned to receive daily low-dose aspirin (100 mg) or a matching placebo and were followed for a median of 4.7 years during the trial. The occurrences of incident MACE and major hemorrhage were tracked for an additional median follow-up of 4.3 years after the trial. The combined median follow-up, including the in-trial and post-trial periods, was 8.3 years. TAKEAWAY: Over the combined follow-up period, participants who received aspirin experienced no significant benefit for MACE compared with those who received placebo. However, during the post-trial period, the use of aspirin was linked to an 18% higher rate of MACE (hazard ratio [HR], 1.18; 95% CI, 1.02-1.37) and a 25% higher rate of myocardial infarction (HR, 1.25; 95% CI, 1.01-1.54) than the use of placebo. Over the combined follow-up period, users of aspirin experienced a 24% higher rate of major hemorrhage than users of placebo (HR, 1.24; 95% CI, 1.10-1.39). Aspirin users also had higher rates of upper gastrointestinal bleeding and bleeding at another site. IN PRACTICE: 'Other research suggests that certain subgroups might benefit from aspirin for primary prevention. However, established bleeding risks and also the possible absence of long-term MACE benefit need to be considered in clinical decision-making,' the researchers reported. SOURCE: This study was led by Rory Wolfe, PhD, of Monash University in Melbourne, Australia. It was published online on August 12, 2025, in the European Heart Journal. LIMITATIONS: The researchers could only ascertain the use of aspirin at the annual visits, which prevented precise tracking of changes between visits. The post-trial comparison was not randomized, which may have influenced the assessment of risks. DISCLOSURES: This study received grants from the National Institute on Aging and National Cancer Institute at the National Institutes of Health in the USA, the National Health and Medical Research Council of Australia, Monash University, and the Victorian Cancer Agency. Aspirin and placebo were provided by Bayer AG. Several authors reported receiving research support or honoraria and having other financial ties with various sources, including Bayer. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.